Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift

Trial Profile

Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Ebselen (Primary)
  • Indications Hearing loss
  • Focus Pharmacodynamics
  • Sponsors Sound Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2013 New trial record
    • 05 Nov 2013 Data from this trial will support an active IND with the FDA for ebselen for the prevention and treatment of noise-induced hearing loss, according to a Sound Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top